<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01455688</url>
  </required_header>
  <id_info>
    <org_study_id>ARV-0112</org_study_id>
    <nct_id>NCT01455688</nct_id>
  </id_info>
  <brief_title>Early Antiviral Therapy for Critically Ill HIV Infected Patients</brief_title>
  <official_title>Early Antiretroviral Therapy for Critically Ill HIV Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Nossa Senhora da Conceicao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Nossa Senhora da Conceicao</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to verify the effect of HAART in critically ill HIV infected
      patients. The current practice is to begin antiviral therapy after ICU discharge, when the
      condition of the patient is more stable. The investigators hypothesis is that the
      investigators can improve outcome of these patients with earlier antiviral therapy in the
      ICU. The investigators just have retrospective studies in this scenario. After admission to
      ICU, patients are assigned to one of two arms: early HAART (within 5 days of ICU admission)
      or conventional therapy (initiation of HAART after ICU discharge). The following data will be
      collected: demographic variables, CD4 count, viral load, drug toxicity, opportunistic
      infection, hemodialysis, mechanical ventilation and vasoactive drug. The patients will be
      followed to determine ICU mortality, hospital mortality and 6-month mortality.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2012</start_date>
  <completion_date type="Actual">June 30, 2016</completion_date>
  <primary_completion_date type="Actual">December 31, 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>4 weeks</time_frame>
    <description>It is a estimative of length of hospital stay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-month mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Early antiviral therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>early HAART</intervention_name>
    <description>Initiation of HAART within 5 days of ICU admission</description>
    <arm_group_label>Early antiviral therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Late HAART</intervention_name>
    <description>Initiation of HAART after ICU discharge</description>
    <arm_group_label>Conventional therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infection

          -  CD4 cell count less than 350 cells/mm3 within 3 months prior to study entry OR CD4
             cell count between 350 cells/mm3 and 500 cells/mm3 if age &gt; 55 years, coinfection with
             HBV or HCV, neoplasia, viral load &gt; 100,000 copies/ml or elevated cardiovascular risk
             OR AIDS-defining illness

        Exclusion Criteria:

          -  Regular use of HAART

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Nossa Senhora da Conceicao</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2011</study_first_submitted>
  <study_first_submitted_qc>October 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2011</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Nossa Senhora da Conceicao</investigator_affiliation>
    <investigator_full_name>Marcio Manozzo Boniatti</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>critically ill patients</keyword>
  <keyword>HIV infection</keyword>
  <keyword>HAART</keyword>
  <keyword>mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

